



Nasdaq TradeTalks Newsletter
Weekly insights on the latest trends
shaping the markets

[SUBSCRIBE](#)

15% COST +0.09% ADBE +0.20% GOOG +0.29% AMGN +0.01% HON +0.01% INTC +1.01% INTU Unchanged NFLX +0.31% ADP Unchanged SBUX -0.02% MRNA

STOCKS



Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

December 10, 2020 — 10:56 am EST

Written by **Zacks Equity Research** for **Zacks** →

Open an account
EXTRADE
from Morgan Stanley

in

f

X



Eli Lilly & Company [LLY](#) announced encouraging top-line data from the phase III study — SURPASS-1 — evaluating its dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA) candidate, tirzepatide, in patients with type II diabetes. Data from the study showed that the candidate is superior to placebo in reducing A1C (blood sugar) levels and body weight from the study baseline.

Shares of Lilly closed 5.8% higher on Dec 9 following the news. The company's shares have gained 20.2% so far this year compared with the [industry's](#) 4% increase.



Innovation
Answered

Learn From Leaders
Reshaping Their Industries

[Read More](#)


Cutting Through
Complexity
in the Financial
System

[DOWNLOAD REPORT](#)


Nasdaq TradeTalks
Where The Voices Of
The Market Meet

[WATCH](#)[MY QUOTES](#)

Eli Lilly & Co.
Exhibit 2041
BPI Labs v. Eli Lilly
IPR2025-01346
Ex. 2041-001



Title	High	Low	Median	Cumulative Return	Annualized Return	Start Date	End Date
LILLY ELI & CO (LLY) % Gr	28.68%	-9.42%	12.80%	20.22%	21.57%	12-31-2019	12-09-2020
Large Cap Pharma Market (ZSI225M) % Gr	4.02%	-23.63%	-9.80%	4.02%	4.28%	12-31-2019	12-08-2020



The SURPASS-1 study evaluated three doses — 5 mg, 10 mg or 15 mg — of tirzepatide monotherapy for 40 weeks in type II diabetes patients who have not been treated with injectable therapy or received oral antidiabetic medicines within three months.

Data from the study showed that treatment with tirzepatide achieved statistically significant reduction in A1C levels and body weight in higher percentage of patients across all doses compared to placebo. Moreover, reduction of A1C level below 7% was achieved in statistically significant higher percentage of participants versus placebo for all dose groups. Please note that A1C level of 7% is the target level recommended by the American Diabetes Association's for people with diabetes. Additionally, the highest dose achieved A1C levels below 5.7%, normal A1C levels seen in people without diabetes, in 51.7% of patients compared to 0.9% for placebo. The highest dose also reduced body weight by 9.5kg or 11% and A1C levels by 2.07%.

Detailed data from the study will be presented at the American Diabetes Association's 81st Scientific Sessions and will be published in a peer-reviewed publication in 2021.


The SURPASS-1 study is part of SURPASS phase 3 global clinical development program for tirzepatide as a potential treatment for type II diabetes. The SURPASS program consists of eight clinical studies including five global registration studies. Further data from this program is anticipated in 2021. Tirzepatide is also in phase III studies for obesity and phase II in NASH.

Lilly has a strong portfolio of medicines to treat diabetes that includes drugs like Tradjenta, Jardiance, Trulicity, Synjardy, Synjardy XR, Glyxambi (a fixed dose combination of Jardiance/metformin), Basalgar and Humalog U-200 KwikPen. However, the diabetes market is extremely crowded with players like **Novartis** [NVO](#), **Sanofi** [SNY](#), **AstraZeneca** [AZN](#) and Merck.




In a separate press release, Lilly announced additional data from a pre-planned primary outcome analysis from the phase III monarchE study evaluating its cancer drug, Verzenio. Data showed that the drug in combination with standard adjuvant endocrine therapy (ET) decreased the risk of breast cancer recurrence by 28.7% compared to adjuvant ET alone in high-risk early breast cancer patients with hormone receptor-positive (HR+) or human epidermal growth factor receptor 2-negative (HER2-) mutation.

Eli Lilly and Company Price



MY QUOTES





[Eli Lilly and Company price](#) | [Eli Lilly and Company Quote](#)


Zacks Rank

Lilly currently carries a Zacks Rank #3 (Hold). You can see [the complete list of today's Zacks #1 Rank \(Strong Buy\) stocks here](#).

Just Released: Zacks' 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.

These 7 were selected because of their superior potential for immediate breakout.



[See these time-sensitive tickers now >>](#)

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. [Click to get this free report](#)

[Novo Nordisk AS \(NVO\): Free Stock Analysis Report](#)

[Sanofi \(SNY\): Free Stock Analysis Report](#)

[AstraZeneca PLC \(AZN\): Free Stock Analysis Report](#)

[Eli Lilly and Company \(LLY\): Free Stock Analysis Report](#)

[To read this article on Zacks.com click here.](#)


[Zacks Investment Research](#)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags STOCKS INVESTING



Zacks



MY QUOTES





Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

More articles by this source →



More Related Articles

MARKETS

Asian Shares Mostly Lower In Cautious Trade; Nikkei Bucks Trend

28 minutes ago • RTTNews

MARKETS

If You'd Invested \$10,000 in SoundHound AI Stock 3 Years Ago, Here's How Much You'd Have Today

39 minutes ago • The Motley Fool

MARKETS

These Are the 5 Most Popular Stablecoins in 2025. Will That Change in 2026?

40 minutes ago • The Motley Fool

MARKETS

Lotus Bakeries H1 Results Climb; Stock Gains

51 minutes ago • RTTNews

MARKETS

This Is the Average 401(k) Balance for Gen X

55 minutes ago • The Motley Fool

MARKETS

Square Enix Q1 Results Slide On Weaker Game Sales, FX Losses

1 hour ago • RTTNews

MARKETS

KKR: Bidco Continues To Urge Assura's Shareholders To Accept Its Best And Final Increased Cash Offer

1 hour ago • RTTNews

MARKETS

1 Brilliant Artificial Intelligence (AI) Stock Down 70% You Might Regret Not Buying on the Dip in August

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

First Name* Last Name*

Email Address*

example@yourdomain.com

Location*

Select... ▼

Job Role*

Select... ▼

Industry*

Select... ▼

Submit

MY QUOTES



Feedback

Final Increased Cash Offer

1 hour ago · RTTNews

Submit

MARKETS

1 Brilliant Artificial Intelligence (AI) Stock Down 70% You Might Regret Not Buying on the Dip in August

1 hour ago · The Motley Fool

MARKETS

Think You Know Costco? Here's 1 Little-Known Fact You Can't Overlook.

1 hour ago · The Motley Fool

MARKETS

2 Brilliant Vanguard Index Funds to Buy With \$1,000 in August and Hold Forever

1 hour ago · The Motley Fool

MARKETS

RTL Group H1 Results Down, Confirms FY25 Outlook

1 hour ago · RTTNews

MARKETS

Is XRP a Millionaire Maker?

1 hour ago · The Motley Fool

MARKETS

MS&AD Insurance Q1 Top-Line Up 4.3%, Net Income Rises 9.1%

1 hour ago · RTTNews

MARKETS

Should You Buy Super Micro Stock After Its 20% Post-Earnings Drop? Wall Street Says This Will Happen Next.

1 hour ago · The Motley Fool

MARKETS

Idemitsu Kosan Q1 Net Income Declines

1 hour ago · RTTNews

Feedback

INVESTOR RELATIONS

CAREERS

MOBILE APPS

TRUST CENTER

ACCESSIBILITY

CONTACT

ADVERTISE

NASDAQ MARKETSITE

NEWSLETTERS

PRIVACY POLICY

COOKIES

LEGAL

DO NOT SELL OR SHARE
MY PERSONAL
INFORMATION



© 2025, Nasdaq, Inc. All Rights Reserved.

MY QUOTES



Think you know crypto? Here's little-known fact you can't overlook.

1 hour ago · The Motley Fool

MARKETS

2 Brilliant Vanguard Index Funds to Buy With \$1,000 in August and Hold Forever

1 hour ago · The Motley Fool

MARKETS

RTL Group H1 Results Down, Confirms FY25 Outlook

1 hour ago · RTTNews

MARKETS

Is XRP a Millionaire Maker?

1 hour ago · The Motley Fool

MARKETS

MS&AD Insurance Q1 Top-Line Up 4.3%, Net Income Rises 9.1%

1 hour ago · RTTNews

MARKETS

Should You Buy Super Micro Stock After Its 20% Post-Earnings Drop? Wall Street Says This Will Happen Next.

1 hour ago · The Motley Fool

MARKETS

Idemitsu Kosan Q1 Net Income Declines

1 hour ago · RTTNews

Feedback

**More styles than you think.
Model portfolios for every client.**

Find a model >

Select models use
MSCI indexes.

BlackRock.

IDRMH0525US-4474260

INVESTOR RELATIONS

CAREERS

MOBILE APPS

TRUST CENTER

ACCESSIBILITY

CONTACT

ADVERTISE

NASDAQ MARKETSITE

NEWSLETTERS

PRIVACY POLICY

COOKIES

LEGAL

DO NOT SELL OR SHARE
MY PERSONAL
INFORMATION



© 2025, Nasdaq, Inc. All Rights Reserved.

MY QUOTES

